Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription

AIDS

Volumn 21, Issue 16, 2007, Pages 2141-2149

  Stevens, Servi J C ^a   Smits, Paul H M ^b   Verkuijlen, Sandra A W M ^a   Rockx, Davy A P ^a   Van Gorp, Eric C M ^b   Mulder, Jan W ^b   Middeldorp, Jaap M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Epstein Barr virus; HIV; IgA; Latency; Viral; Viral load

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LATENT MEMBRANE PROTEIN 1; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS DNA;

ANALYTICAL EQUIPMENT; ANALYTICAL PARAMETERS; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; DENMARK; DNA TRANSCRIPTION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PLASMA; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; TRANSCRIPTION REGULATION; VIRUS CAPSID; VIRUS CARRIER; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSCRIPTION;

ADULT; ANTIGENS, VIRAL; AUTORADIOGRAPHY; CAPSID PROTEINS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HIV SEROPOSITIVITY; HUMANS; IMMUNOGLOBULIN A; LYMPHOMA, B-CELL; TRANSCRIPTION, GENETIC; VIRAL LOAD; VIRUS LATENCY;

EID: 37349080918     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282eeeba0     Document Type: Article

References (55)

1. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 70: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. Lyon, France: IARC; 1997.
2. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001; 1:75-82.
3. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol 2000; 165:2975-2981.
4. Thorley-Lawson DA. EBV: schizophrenic but not dysfunctional. EBV Rep 1999; 6:158-163.
5. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757-768.
6. Van Grunsven WM, Spaan WJ, Middeldorp JM. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J Infect Dis 1994; 170:13-19.
7. Stevens SJC, Verschuuren EAM, Pronk I, Van der Bij W, Harmsen M, The TH, et al. Frequent monitoring of EBV DNA load in unfractionated whole blood is essential for early detection of PTLD in high risk patients. Blood 2001; 97:1165-1171.
8. Stevens SJC, Vervoort MBHJ, Van den Brule AJC, Meenhorst PL, Meijer CJLM, Middeldorp JM. Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive polymerase chain reaction. J Clin Microbiol 1999; 37:2852-2857.
9. Laroche C, Drouet EB, Brousset P, Pain C, Boibieux A, Biron F, et al. Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas. J Med Virol 1995; 46:66-74.
10. Fan H, Kim SC, Chima CO, Israel BF, Lawless KM, Eagan PA, et al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 2005; 75:59-69.
11. Bonnet F, Jouvencel AC, Parrens M, Leon MJ, Cotto E, Garrigue I, et al. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 2006; 36:258-263.
12. Stevens SJC, Blank BSN, Smits PHM, Meenhorst PL, Middeldorp JM. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy quantitative EBV serology. AIDS 2002; 16:993-1001.
13. Van Baarle D, Hovenkamp E, Callan MF, Wolthers KC, Kostense S, Tan LC, et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001; 98:146-155.
14. Dehee A, Asselot C, Piolot T, Jacomet C, Rozenbaum W, Vidaud M, et al. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol 2001; 65:543-552.
15. Righetti E, Ballon G, Ometto L, Cattelan AM, Menin C, Zanchetta M, et al. Dynamics of Epstein-Barr virus in HIV-infected subjects on highly active antiretroviral therapy. AIDS 2002; 16:63-73.
16. Piriou ER, Van Dort K, Nanlohy NM, Miedema F, Van Oers MH, Van Baarle D. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol 2004; 172:6931-6937.
17. Ling PD, Vilchez RA, Keitel WA, Poston DG, Peng RS, White ZS, et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003; 37:1244-1249.
18. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 2004; 101:239-244.
19. Brink AA, Dukers DF, Van den Brule AJ, Oudejans JJ, Middeldorp JM, Meijer CJ, et al. Presence of Epstein-Barr virus latency type III at the single cell level in posttransplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol 1997; 50:911-918.
20. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, Van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
21. Stevens SJC, Verkuijlen SAWM, Middeldorp JM. Quantitative detection of Epstein-Barr virus DNA in clinical specimens by rapid real-time PCR targeting a highly conserved region of EBNA-1. Meth Mol Biol 2005; 292:15-25.
22. Stevens SJC, Verkuijlen SAWM, Hariwiyanto B, Harijadi A, Fachiroh J, Paramita D, et al. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol 2005; 43:3066-3073.
23. Brink AATP, Vervoort MBHJ, Middeldorp JM, Meijer CJLM, Van den Brule AJC. Nucleic acid sequence-based amplification, a new method for analysis of spliced and unspliced Epstein-Barr virus latent transcripts, and its comparison with reverse transcriptase PCR. J Clin Microbiol 1998; 36:3164-3169.
24. Deiman B, Van Aarle P, Sillekens P. Characteristics applications of nucleic acid sequence-based amplification (NASBA). Mol Biotechnol 2000; 20:163-167.
25. Van Beek J, Brink AA, Vervoort MB, Van Zijp MJ, Meijer CJ, Van den Brule AJ, et al. In vivo transcription of the Epstein-Barr virus (EBV) BamHI-A region without associated in vivo BARF0 protein expression in multiple EBV-associated disorders. J Gen Virol 2003; 84:2647-2659.
26. Stevens SJC, Brink AATP, Middeldorp JM. Profiling of Epstein-Barr virus latent RNA expression in clinical specimens by gene-specific multiprimed cDNA synthesis and PCR. Methods Mol Biol 2005; 292:27-38.
27. Meij P, Vervoort MB, Bloemena E, Schouten TE, Schwartz C, Grufferman S, et al. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J Med Virol 2002; 68:370-377.
28. Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, et al. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J Med Virol 2005; 75:593-602.
29. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, et al. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol 2006; 44:1459-1467.
30. Chan KC, Zhang J, Chan AT, Lei K, Leung SF, Chan LY, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma lymphoma patients. Cancer Res 2003; 63:2028-2032.
31. Stevens SJC, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 29:1211-1216.
32. Pegtel DM, Middeldorp J, Thorley-Lawson DA. Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J Virol 2004; 78:12613-12624.
33. Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005; 79:1296-1307.
34. Brengel-Pesce K, Morand P, Schmuck A, Bourgeat MJ, Buisson M, Bargues G, et al. Routine use use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol 2002; 66:360-369.
35. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, Kryscio RJ. High Prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. J Clin Microbiol 2006; 44:2409-2415.
36. Walling DM, Flaitz CM, Nichols CM, Hudnall SD, Adler-Storthz K. Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. J Infect Dis 2001; 184:1499-1507.
37. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol 2000; 74:7610-7618.
38. Herrmann K, Frangou P, Middeldorp J, Niedobitek G. Epstein-Barr virus replication in tongue epithelial cells. J Gen Virol 2002; 83:2995-2998.
39. Ng WT, Yau TK, Yung RW, Sze WM, Tsang AH, Law AL, Lee AW. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005; 113:998-1001.
40. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer 1984; 33:27-32.
41. Daibata M, Humphreys RE, Takada K, Sairenji T. Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J Immunol 1990; 144:788-793.
42. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A 2005; 2:18093-18098.
43. Fu Z, Cannon MJ. Functional analysis of the CD4(R) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol 2000; 4:6675-6679.
44. De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001; 15:957-964.
45. Takeuchi H, Kobayashi R, Hasegawa M, Hirai K. Detection of latent infection by Epstein-Barr virus in peripheral blood cells of healthy individuals and in nonneoplastic tonsillar tissue from patients by reverse transcription-polymerase chain reaction. J Virol Methods 1996; 58 (1-2):81-89.
46. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68:7374-7385.
47. Chen H, Smith P, Ambinder RF, Hayward SD. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. Blood 1999; 93:3026-3032.
48. Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000; 96:4055-4063.
49. Smith P. Epstein-Barr virus complementary strand transcripts (CSTs/BARTs) and cancer. Semin Cancer Biol 2001; 11:469-476.
50. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathogen 2006; 2:e23.
51. Ikeda M, Fukuda M, Longnecker R. Function of latent membrane protein 2A. In: Epstein-Barr virus. Edited by Robertson ES. Norfolk, UK: Caister Press; 2005.
52. Dykstra ML, Longnecker R, Pierce SK. Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 2001; 14:57-67.
53. Miller CL, Lee JH, Kieff E, Longnecker R. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 1994; 91:772-776.
54. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999; 190:567-576.
55. Schittek B, Rajewsky K. Maintenance of B-cell memory by long-lived cells generated from proliferating precursors. Nature 1990; 346:749-751.